{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T05:47:02Z","timestamp":1791697622418,"version":"4.3.4"},"reference-count":12,"publisher":"SAABRON PRESS","issue":"2","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>We present the case of a dialyzed patient with relapsed IgA and lambda free light chain multiple myeloma treated with elranatamab. Despite end-stage renal impairment, the treatment with anti-B cell maturation antigen (BCMA)xCD3 bispecific antibody proved to be feasible, without unexpected side effects. Increased attention to infectious risk is crucial for these doubly fragile patients.<\/jats:p>","DOI":"10.46989\/001c.116800","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T16:17:53Z","timestamp":1715012273000},"source":"Crossref","is-referenced-by-count":15,"title":["Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis"],"prefix":"10.46989","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9463-2823","authenticated-orcid":false,"given":"Zo\u00e9","family":"Van de Wyngaert","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9 ; Centre de Recherche Saint-Antoine INSERM UMRs938, Paris, France"},{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint Antoine, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Romera-Martinez","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint Antoine, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Chedeville","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint Antoine, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Musiu","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint Antoine, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souhila","family":"Ikhlef","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint Antoine, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Jonca","sequence":"additional","affiliation":[{"name":"Service de m\u00e9decine nucl\u00e9aire, Tenon Hospital, , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9 ; Centre de Recherche Saint-Antoine INSERM UMRs938, Paris, France"},{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint Antoine, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Florent","family":"Malard","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9 ; Centre de Recherche Saint-Antoine INSERM UMRs938, Paris, France"},{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint Antoine, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Beatrice Z. Sim","year":"2023","journal-title":"Blood Cancer Journal","ISSN":"https:\/\/id.crossref.org\/issn\/2044-5385","issn-type":"print"},{"issue":"10","key":"ref2","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/blood.2022017726","article-title":"Bispecifics need a mindful pause","volume":"140","author":"Cristina Toffalori","year":"2022","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"Supplement 1","key":"ref3","doi-asserted-by":"publisher","first-page":"10020","DOI":"10.1182\/blood-2022-168836","article-title":"Pseudoprogression and Sarcoidosis-like Phenomena after CART-Cells and Bispecific Antibodies in Multiple Myeloma","volume":"140","author":"Alexander Leipold","year":"2022","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"Supplement 1","key":"ref4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1182\/blood-2022-162440","article-title":"Efficacy and Safety of Elranatamab in Patients with Relapsed\/Refractory Multiple Myeloma Na\u00efve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study","volume":"140","author":"Nizar Jacques Bahlis","year":"2022","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"6","key":"ref5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/nejmoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Philippe Moreau","year":"2022","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"4","key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17412","article-title":"Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure","volume":"193","author":"Ayumi Kuzume","year":"2021","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"15_suppl","key":"ref7","doi-asserted-by":"publisher","first-page":"8519","DOI":"10.1200\/jco.2020.38.15_suppl.8519","article-title":"DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed\/refractory multiple myeloma (RRMM) and renal impairment.","volume":"38","author":"Hans Chulhee Lee","year":"2020","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"12","key":"ref8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41408-021-00592-3","article-title":"\u201cReal-life\u201d data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma\u2014the Mayo Clinic experience","volume":"11","author":"I. Vaxman","year":"2021","journal-title":"Blood Cancer Journal","ISSN":"https:\/\/id.crossref.org\/issn\/2044-5385","issn-type":"print"},{"issue":"3","key":"ref9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"Surbhi Sidana","year":"2023","journal-title":"Haematologica","ISSN":"https:\/\/id.crossref.org\/issn\/1592-8721","issn-type":"print"},{"key":"ref10","article-title":"Study for Desensitization of Chronic Kidney Disease in Adult Patients in Need of a Kidney Transplant Who Are Highly Sensitized to Human Leukocyte Antigen. NCT05092347"},{"issue":"5","key":"ref11","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T \u2010cell and bispecific antibody therapy in multiple myeloma.","volume":"203","author":"Meera Mohan","year":"2023","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"13","key":"ref12","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Farah Mazahreh","year":"2023","journal-title":"Blood Advances","ISSN":"https:\/\/id.crossref.org\/issn\/2473-9529","issn-type":"print"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/116800-elranatamab-treatment-in-a-multiple-myeloma-patient-undergoing-renal-dialysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T05:34:07Z","timestamp":1791696847000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/116800-elranatamab-treatment-in-a-multiple-myeloma-patient-undergoing-renal-dialysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":12,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.116800","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]}}}